HC Wainwright Lowers Checkpoint Therapeutics (NASDAQ:CKPT) Price Target to $20.00

Checkpoint Therapeutics (NASDAQ:CKPT) had its target price cut by research analysts at HC Wainwright from $34.00 to $20.00 in a note issued to investors on Monday, Benzinga reports. The firm presently has a “buy” rating on the stock.

Checkpoint Therapeutics Stock Up 4.9 %

CKPT traded up $0.11 during trading on Monday, reaching $2.36. 380,446 shares of the stock traded hands, compared to its average volume of 474,673. The stock has a market capitalization of $84.22 million, a PE ratio of -0.85 and a beta of 1.25. Checkpoint Therapeutics has a 12 month low of $1.30 and a 12 month high of $3.62. The stock’s 50-day moving average is $2.20 and its 200 day moving average is $1.97.

Checkpoint Therapeutics (NASDAQ:CKPT) last posted its quarterly earnings data on Friday, May 10th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.04. As a group, equities research analysts anticipate that Checkpoint Therapeutics will post -1.21 EPS for the current year.

Insider Buying and Selling at Checkpoint Therapeutics

In other news, CFO William Garrett Gray sold 13,038 shares of the business’s stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $2.06, for a total transaction of $26,858.28. Following the completion of the sale, the chief financial officer now directly owns 672,186 shares of the company’s stock, valued at $1,384,703.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO James F. Oliviero III sold 24,610 shares of the business’s stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $2.05, for a total transaction of $50,450.50. Following the completion of the transaction, the chief executive officer now directly owns 1,977,170 shares of the company’s stock, valued at $4,053,198.50. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO William Garrett Gray sold 13,038 shares of the firm’s stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $2.06, for a total transaction of $26,858.28. Following the completion of the sale, the chief financial officer now owns 672,186 shares of the company’s stock, valued at approximately $1,384,703.16. The disclosure for this sale can be found here. Insiders own 2.10% of the company’s stock.

Institutional Trading of Checkpoint Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Armistice Capital LLC increased its holdings in shares of Checkpoint Therapeutics by 17.5% during the 4th quarter. Armistice Capital LLC now owns 2,426,000 shares of the company’s stock worth $5,556,000 after purchasing an additional 362,000 shares during the period. Vanguard Group Inc. increased its stake in shares of Checkpoint Therapeutics by 67.4% during the first quarter. Vanguard Group Inc. now owns 917,894 shares of the company’s stock worth $1,882,000 after purchasing an additional 369,586 shares during the period. B. Riley Wealth Advisors Inc. raised its position in shares of Checkpoint Therapeutics by 232.3% in the 4th quarter. B. Riley Wealth Advisors Inc. now owns 163,350 shares of the company’s stock valued at $374,000 after buying an additional 114,200 shares in the last quarter. Choreo LLC boosted its stake in shares of Checkpoint Therapeutics by 12.2% during the second quarter. Choreo LLC now owns 65,002 shares of the company’s stock valued at $133,000 after purchasing an additional 7,080 shares in the last quarter. Finally, 180 Wealth Advisors LLC acquired a new stake in Checkpoint Therapeutics during the 2nd quarter worth about $96,000. Institutional investors own 22.00% of the company’s stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.